Oncology
Advanced Biliary Tract Carcinoma
4
Pipeline Programs↗
4
Active Trials↗
4
Companies Involved↗
Advanced Biliary Tract Carcinoma is an early-stage landscape with 4 programs across 4 companies. The most active players are Pfizer, Eastern Cooperative Oncology Group, Teva.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 24
Phase 3
No programs
Approved
No programs
Analysis
Trial Status
14
clinical trials
Completed6 · 43%
Unknown status3 · 21%
Not yet recruiting2 · 14%
Terminated1 · 7%
Recruiting1 · 7%
Active, not recruiting1 · 7%
Clinical Trials
Trial Activity
14 trials
MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Recruiting·—·Phase 2·NCT07036380·75 enrolled
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma
Completed·—·Phase 2·NCT04550624·27 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)